Document is current
Any future updates will be listed below
-
Authors
Bosio, Alberto
Cerretti, Giulia
Padovan, Marta
Del Bianco, Paola
Polano, Maurizio
Mandruzzato, Susanna
Indraccolo, Stefano
Manara, Renzo
Librizzi, Giovanni
Caccese, Mario
Corrà, Martina
Maccari, Marta
Lonardi, Sara
De Salvo, Gian Luca
Lombardi, Giuseppe
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 23 July 2025
First Online: 4 August 2025
Declarations
:
: All participating patients will provide written informed consent. Local investigators, who are board-certified physicians with up-to-date Good Clinical Practice (GCP) certification, confirmed delegation, and completed training for clinical trial activities, will be responsible for obtaining informed consent. Ethics approval for this study was obtained from the Ethics Committee of the Istituto Oncologico Veneto (Padua, Italy). The study was approved on June 5th, 2024, with protocol version 1.1. The trial is registered under EuCT number 2024–510954-28.
: This manuscript does not include any personally identifiable information from patients. No images or clinical details that could identify participants are presented in this report, nor will they be included in any future publications of the trial results. It is intended that the study design and main results will be published on . In addition, the results of the study may be published as scientific literature.
: AB declares he has no competing interests. GC declares he has no competing interests. MP declares he has no competing interests. PDB declares he has no competing interests. MP declares he has no competing interests. SM declares he has no competing interests. SI declares he has no competing interests. RM declares he has no competing interests. GL declares he has no competing interests. MC declares he has no competing interests. MC declares he has no competing interests. MM declares he has no competing interests. SL has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Amgen, Merck Serono, Lilly, Servier, AstraZeneca, Incyte, Daiichi Sankyo, Bristol-Myers Squibb, MSD, Astellas Pharma, Bayer, GlaxoSmithKline, Takeda, Rottapharm Biotech, Beigene, Nimbus Therapeutics, Fosun Pharma, Roche, Pierre Fabre, GlaxoSmithKline. GDS declares he has no competing interests. GL has received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, GlaxoSmithKline, Cecava, TME Pharma, Genenta Science, Novocure, Servier, Novartis, Janssen Oncology, Brain Health Solutions, health4u, Braun Travacare, CarThera.
